Showing 2 posts of 2 posts found.


FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

Latest content